---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020616"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:56:33.357716+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# VK2735 Phase 2 meets endpoints: up to 14.7% weight loss, 88% achieve ≥10% loss

## Summary
- Primary and all secondary endpoints met; up to 14.7% mean weight loss from baseline (13.1% placebo-adjusted) after 13 weeks.
- Up to 88% of VK2735-treated patients achieved ≥10% weight loss vs 4% for placebo.
- No weight loss plateau observed; reductions progressive through week 13.
- Well-tolerated: 92% of drug-related TEAEs mild/moderate; low discontinuation (13% vs 14% placebo).
- Company plans FDA meeting to discuss next steps; oral formulation data expected this quarter.

## SEC filing metadata
- accession: 0000950170-24-020616
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017024020616/0000950170-24-020616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017024020616/vktx-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020616
- JSON: https://secwatch.observer/filing/0000950170-24-020616.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.